I-Mab (Hangzhou) key facts
- Manufacturer of macromolecular antibody drugs focused on integrated biopharmaceutical research and production.
- It has raised $154.3M; the latest was Later Stage VC ($84.2M) in Sep 2025.
- Notable investors include HSG (Hong Kong), CICC Capital, Oriental Fortune Capital, Tailong VC, HaiBang Ventures — 23 tracked in total.
- Status: Privately Held (backing).
Who backs I-Mab (Hangzhou)
23+- ·The complete investor list: 23 names
- ·Watch I-Mab (Hangzhou): the Monday email on marks, rounds and moves
I-Mab (Hangzhou) funding rounds
No funding rounds for I-Mab (Hangzhou) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
I-Mab (Hangzhou) investors
23 investors are on record for I-Mab (Hangzhou), including HSG (Hong Kong), CICC Capital, Oriental Fortune Capital and Tailong VC.
About I-Mab (Hangzhou)
Manufacturer of macromolecular antibody drugs focused on integrated biopharmaceutical research and production. The company specailises in drug discovery, process development, technology transfer, preclinical and clinical research, enabling delivery of high-efficacy antibody therapies through a unified R&D and manufacturing framework.
- Sector
- Healthcare
- HQ
- Hangzhou, China
- Founded
- 2019
- Website
- imab-hz.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
I-Mab (Hangzhou) doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.